In the Oct 17 2017 presentation on slide 23, DM showed the pre-clinical data for a triple-negative breast cancer model, in which ZEN-3694 in combo with other drugs worked very well. We've seen that before and we've known Zenith is interested in the breast cancer space. However, DM said something in the presentation that I think is new:

"In breast cancer we'd probably start with ER-positive breast cancer. Our data in that area is actually even better."

Stay tuned..........